Nurix Therapeutics Inc (OQ:NRIX)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Apr 16, 2024 06:21 pm ET

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which includes 1,750,000 shares issued upon the...

Apr 11, 2024 11:38 pm ET

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common stock at a price to the public of $15.00 per share. In addition, and in lieu of common stock, Nurix...

Apr 11, 2024 04:00 pm ET

Nurix Therapeutics Announces Proposed Public Offering

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that it has commenced an underwritten...

Apr 10, 2024 07:00 am ET

Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Apr 09, 2024 01:15 pm ET

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the presentation of the first...

Apr 09, 2024 07:00 am ET

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6

Apr 03, 2024 07:00 am ET

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Apr 02, 2024 07:00 am ET

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

Mar 25, 2024 07:00 am ET

Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)

Mar 20, 2024 09:40 am ET

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting

Mar 11, 2024 07:00 am ET

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial

Mar 06, 2024 04:00 pm ET

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Mar 05, 2024 04:30 pm ET

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting

Feb 15, 2024 04:00 pm ET

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update

Feb 01, 2024 04:01 pm ET

Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader

Jan 16, 2024 04:01 pm ET

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL

Jan 08, 2024 07:00 am ET

Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases

Jan 02, 2024 04:01 pm ET

Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D.,...

Dec 13, 2023 04:32 pm ET

Judith A. Reinsdorf and Katherine M. Sandstrom Named to Toll Brothers Board of Directors

Toll Brothers, Inc. (NYSE: TOL) (TollBrothers.com), the nation’s leading builder of luxury homes, today announced that Judith A. Reinsdorf and Katherine M. Sandstrom have joined the Company’s Board of Directors. In addition, Carl B. Marbach, age...

Dec 11, 2023 12:00 pm ET

Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today presented positive clinical data from...

Dec 04, 2023 04:01 pm ET

Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting

Nov 11, 2023 07:49 am ET

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Nurix Therapeutics, Inc. (NASDAQ: NRIX) and Encourages Investors to Contact the Firm

Kaskela Law LLC announces that it is investigating Nurix Therapeutics, Inc. (NASDAQ: NRIX) (“Nurix”) on behalf of the company’s investors. Since July 2023, shares of Nurix’s common stock have declined in value from a trading price of over $10.00...

Nov 07, 2023 04:01 pm ET

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nov 02, 2023 09:00 am ET

Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting

Nov 01, 2023 04:01 pm ET

Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial

Oct 12, 2023 04:01 pm ET

Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

Oct 02, 2023 11:00 am ET

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Nurix Therapeutics, Inc. (NASDAQ: NRIX) and Encourages Investors to Contact the Firm

Kaskela Law LLC announces that it is investigating Nurix Therapeutics, Inc. (NASDAQ: NRIX) (“Nurix”) on behalf of the company’s investors. Since January 2023, shares of Nurix’s common stock have declined in value from a trading price of over...

Sep 07, 2023 07:00 am ET

Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer T

Aug 31, 2023 04:01 pm ET

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Jul 13, 2023 04:01 pm ET

Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

Jun 14, 2023 07:00 am ET

Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cel

May 09, 2023 04:01 pm ET

Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

Apr 17, 2023 02:30 pm ET

Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad

Apr 13, 2023 04:01 pm ET

Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

Apr 11, 2023 04:01 pm ET

Nurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

Mar 20, 2023 08:30 am ET

Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479

Mar 20, 2023 08:30 am ET

Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479

Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX‑0479. This bivalent degrader, designated GS-6791, is the first development candidate resulting from the

Mar 14, 2023 04:45 pm ET

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting

Mar 06, 2023 04:01 pm ET

Nurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Feb 09, 2023 04:15 pm ET

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update

Feb 08, 2023 04:01 pm ET

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Jan 09, 2023 08:35 am ET

Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities

Jan 04, 2023 07:01 am ET

Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

Dec 15, 2022 04:01 pm ET

Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

Dec 12, 2022 05:30 pm ET

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

Dec 07, 2022 04:01 pm ET

Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting

Nov 10, 2022 09:00 am ET

Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in

Nov 10, 2022 09:00 am ET

Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Ma

Nov 03, 2022 09:00 am ET

Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

Nov 02, 2022 04:01 pm ET

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s...

Oct 26, 2022 07:00 am ET

Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summi

Oct 21, 2022 09:32 am ET

Thinking about buying stock in Purecycle Technologies, Sellas Life Sciences, Nurix Therapeutics, Pineapple Energy, or 89bio?

NEW YORK, Oct. 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PCT, SLS, NRIX, PEGY, and ETNB.

Oct 19, 2022 09:00 am ET

Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) Summit

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it will make several presentations, including a Keynote Plenary presentation by Arthur T. Sands,...

Oct 06, 2022 04:01 pm ET

Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the third quarter ended August 31, 2022 and provided a corporate update. “The...

Oct 05, 2022 08:00 am ET

Nurix Therapeutics Announces Six Poster Presentations at the Upcoming Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced six poster presentations at the upcoming Society for Immunotherapy of Cancer’s (SITC) 37th Annual...

Sep 14, 2022 04:01 pm ET

Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Edward C. Saltzman to its board of directors. Mr. Saltzman has over 30 years of...

Aug 31, 2022 04:01 pm ET

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following...

Aug 03, 2022 07:00 am ET

Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Eric Schlezinger, J.D. has joined the company as chief people officer. Mr. Schlezinger is an...

Jul 08, 2022 08:00 am ET

Nurix Therapeutics Announces $40 Million Registered Direct Offering

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has entered into a securities purchase agreement with two healthcare-focused investment funds...

Jul 07, 2022 05:03 pm ET

Nurix Therapeutics Announces $55 Million Registered Direct Offering

Jul 07, 2022 04:05 pm ET

Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the second quarter ended May 31, 2022 and provided a corporate update. “In the...

Jun 30, 2022 08:00 am ET

Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the company's...

Jun 10, 2022 07:00 am ET

Nurix Therapeutics Will Present Trial in Progress Posters for Two Clinical Programs at the 2022 Annual European Hematology Association (EHA) Congress

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the company will present clinical trial design details for two of its wholly-owned investigative...

Jun 03, 2022 07:00 am ET

Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

May 26, 2022 07:00 am ET

Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has initiated the first of several potential Phase 1b expansion cohorts in its ongoing Phase 1 trial of...

May 17, 2022 07:00 am ET

Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the first patient has been dosed in its Phase 1a/1b study to evaluate orally available small...

May 11, 2022 04:02 pm ET

Nurix Therapeutics Announces Participation in the 2022 RBC Capital Markets Global Healthcare Conference

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in...

May 09, 2022 04:02 pm ET

Nurix Therapeutics to Host R&D Day on May 26, 2022

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced it will host a research & development (R&D) day for analysts and investors that will be held on...

Apr 08, 2022 01:02 pm ET

Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced the presentation of preclinical data that support the clinical development of investigative therapies...

Apr 07, 2022 04:01 pm ET

Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the first quarter ended February 28, 2022 and provided a corporate update. “In...

Apr 05, 2022 07:00 am ET

Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the first patient has been dosed in its Phase 1 clinical trial of DeTIL-0255, a drug-enhanced...

Apr 04, 2022 04:01 pm ET

Nurix Therapeutics Announces Participation in the 21st Annual Needham Virtual Healthcare Conference

Mar 29, 2022 04:01 pm ET

Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the innovative medicine...

Mar 09, 2022 04:01 pm ET

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Mar 08, 2022 04:47 pm ET

Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Programs at the American Association for Cancer Research Annual Meeting

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical data supporting its NX-2127 and DeTIL-0255 clinical programs will be presented at the upcoming...

Feb 10, 2022 04:01 pm ET

Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference

Jan 27, 2022 04:01 pm ET

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the fourth quarter and fiscal year ended November 30, 2021 and provided a...

Jan 10, 2022 07:00 am ET

Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today outlined key objectives and anticipated milestones for 2022 and provided an overview of recent progress. “2021 was a...

Jan 03, 2022 04:01 pm ET

Nurix Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix will present an overview of...

Dec 12, 2021 09:00 am ET

Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the grant of a Clinical Trial Authorization (CTA) for NX-5948, a potent and selective degrader of Bruton’s tyrosine...

Nov 12, 2021 07:09 am ET

Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that the Food and Drug Administration (FDA) has cleared Nurix’s Investigational New Drug Application (IND) for its...

Nov 12, 2021 07:07 am ET

Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the presentation of preclinical studies demonstrating that its CBL-B inhibitor, NX-0255, enhances the number and...

Nov 09, 2021 04:01 pm ET

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Oct 27, 2021 07:00 am ET

Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced initial data demonstrating clinically meaningful degradation of Bruton’s tyrosine kinase (BTK) in patients with...

Oct 26, 2021 04:02 pm ET

Nurix Therapeutics to Present Initial Target Degradation Data from First Phase 1 Trial of NX-2127 in B Cell Malignancies at the 4th Annual Targeted Protein Degradation Summit

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that the Company will present initial pharmacokinetic and pharmacodynamic data from its first-in-human, Phase 1...

Oct 21, 2021 07:00 am ET

Nurix Therapeutics to Participate in the 4th Annual Targeted Protein Degradation Summit

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Nurix’s president and chief executive officer Arthur T. Sands, M.D., Ph.D., and Nurix’s chief scientific officer...

Oct 14, 2021 04:02 pm ET

Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the third quarter ended August 31, 2021 and provided a corporate update. “With the recent...

Sep 30, 2021 07:00 am ET

Nurix Therapeutics Expands its Board of Directors with the Addition of Two Industry Leaders

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointments of Judith A. Reinsdorf and Paul M. Silva to its board of directors, effective October 1, 2021. Ms....

Jul 13, 2021 04:01 pm ET

Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

Nurix Therapeutics Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the second quarter ended May 31, 2021 and provided a corporate update. “Our first clinical...

Jun 21, 2021 04:01 pm ET

Nurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President, Product Development

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Stefani A. Wolff has joined the company as chief operating officer and executive vice president of product...

Jun 02, 2021 07:00 am ET

Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reduction of Inflammation in a Model of Autoimmune Disease

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the presentation of preclinical data from its NX-5948 program, demonstrating that daily oral dosing of NX-5948...

Jun 01, 2021 04:00 pm ET

Nurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its Board of Directors

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Clay Siegall, Ph.D., to its board of directors. Dr. Siegall is a co-founder of Seagen Inc....

May 21, 2021 07:00 am ET

Nurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual Congress

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical data from its NX-5948 program will be presented at the upcoming European Alliance of Associations...

May 11, 2021 07:00 am ET

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that members of Nurix management team will participate in the following conferences in May: RBC Capital Markets...

Apr 13, 2021 04:01 pm ET

Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

Nurix Therapeutics Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the first quarter ended February 28, 2021 and provided a corporate update. “We began 2021 with...

Apr 07, 2021 07:00 am ET

Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s chief executive officer, will participate in a fireside chat at the 20th...

Mar 16, 2021 09:31 am ET

Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it is part of a collaboration sponsored by Alex’s Lemonade Stand Foundation (ALSF), a leading funder of...

Mar 10, 2021 05:12 pm ET

Nurix Therapeutics Announces Presentation of NX-1607 Preclinical Data at AACR

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced presentation of data from its NX-1607 program at the American Association for Cancer Research 2021 annual meeting...

Mar 09, 2021 04:01 pm ET

Nurix Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the closing of its underwritten public offering of 5,175,000 shares of its common stock at a public offering price of...

Mar 09, 2021 07:30 am ET

Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix’s chief executive officer, will participate and present at the following...

Mar 04, 2021 08:01 pm ET

Nurix Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a public offering price of...

Mar 02, 2021 04:15 pm ET

Nurix Therapeutics Announces Launch of Proposed Public Offering of Common Stock

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. All of the shares of...

Feb 16, 2021 04:01 pm ET

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the fourth quarter and fiscal year ended November 30, 2020 and provided a corporate update. “We...

Jan 07, 2021 07:00 am ET

Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degradation Therapies

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the expansion of its global strategic collaboration with Sanofi to discover, develop and commercialize a pipeline of...

Jan 05, 2021 07:00 am ET

Nurix Therapeutics Announces Presentation at 39th Annual J.P. Morgan Healthcare Conference

Dec 07, 2020 10:01 am ET

Nurix Therapeutics Presents Preclinical Data at 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the presentation of key preclinical data from its lead program, NX-2127, for the potential treatment of B-cell...

Nov 09, 2020 07:00 am ET

Nurix Therapeutics to Present at Upcoming Investor Conferences

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will be presenting at the following healthcare investor conferences: Stifel 2020 Virtual Healthcare...

Nov 04, 2020 04:01 pm ET

Nurix Therapeutics to Present Preclinical Data at Upcoming 5th Medicinal Chemistry & Protein Degradation Summit and 62nd ASH Annual Meeting and Exposition

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will present data on its novel targeted protein degradation platform at the upcoming 5th Medicinal Chemistry...

Oct 26, 2020 08:00 am ET

Nurix Therapeutics Announces Appointment of Robert Tjian as Chairman of Scientific Advisory Board and His Resignation from the Board of Directors

Nurix Therapeutics, Inc. (Nasdaq: NRIX), today announced that, based on his desire to lead Nurix’s Scientific Advisory Board, Robert Tjian, Ph.D. has resigned from the Company’s Board of Directors effective November 1, 2020. Dr. Tjian (“Tij”) has...

Oct 14, 2020 04:05 pm ET

Ad blocking detected

Nurix Therapeutics Inc (OQ:NRIX)

Business Focus: Bio Therapeutic Drugs